Parabilis Medicines’ Nasdaq debut continued the biotech IPO rebound after the company raised $670 million, following other mega-listings that have restored public-market momentum. The reporting contrasts the current listing wave with a multi-year IPO lull, driven by previously constrained venture deployment and shifting macro conditions. The story also notes that investor appetite returned even as policy uncertainty persisted, including continued FDA leadership gaps. It frames the current cycle as a “snowball” effect of previously raised capital seeking outlets into public equity and follow-on transactions. For sector participants, the listings are a near-term indicator of improved liquidity for growth-stage funding, pipeline monetization, and acquisition readiness.